BullFrog AI Publishes Annual Letter to Shareholders

Core Insights - BullFrog AI Holdings, Inc. has made significant progress in 2025, positioning itself for transformative growth in 2026 through advancements in technology, commercial execution, and external validation [2][3][15] Commercial Development - The company is engaged in advanced discussions with large pharmaceutical organizations for potential commercial transactions, including out-licensing and discovery research collaborations, indicating a growing recognition of its platform's value [4][15] - A commercial collaboration with Sygnature Discovery was established in Q2 2025, expected to generate significant revenue through 2028, enhancing BullFrog AI's commercial reach [5][15] - Internal sales and marketing efforts have been expanded to support clinical trial optimization solutions, leveraging successful use cases in oncology and neuroscience to drive engagement [6][15] Technological Advancements - The evolution of BullFrog AI's technology into a modular, enterprise-grade solutions stack supports broader commercial adoption, allowing clients to deploy targeted solution modules [7][8] - The launch of bfPREP™, an AI-powered data preparation tool, addresses challenges in transforming unstructured data into AI-ready datasets, significantly reducing preparation timelines [12][13] Scientific Validation - A collaboration with Eleison Pharmaceuticals represents a significant real-world deployment of BullFrog AI's platforms in a late-stage oncology program, demonstrating the ability to deliver actionable insights in clinical development [9][10] - Insights from this collaboration will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium, which is expected to enhance commercial engagement opportunities [11][15] Financial Strategy - The company maintains a disciplined approach to capital allocation with an annual burn of approximately $6.2 million, creating substantial operating leverage as commercial opportunities convert [14][15] - Additional financing flexibility has been established, including a $10 million equity line of credit, to support execution as opportunities advance [14] Future Outlook - BullFrog AI anticipates several catalysts in 2026, including continued commercialization through Sygnature Discovery, expanding engagement around bfPREP™, and executing contracts with large pharmaceutical companies [16][17] - The foundation built in 2025 is expected to translate into meaningful commercial outcomes, reinforcing the company's role as a trusted partner in data-driven drug development [17]